The DEDICATE trial of TAVR vs SAVR, more on renal denervation, inclisiran, and marketing disguised as science are the topics John Mandrola, MD, discusses in today’s podcast.


This podcast is intended for healthcare professionals only.


To read a partial transcript or to comment, visit:


https://www.medscape.com/twic


I. TAVR vs SAVR


TAVI Comparable With SAVR in Lower-Risk Aortic Stenosis


https://www.medscape.com/viewarticle/...


• DEDICATE https://www.nejm.org/doi/full/10.1056...

• Partner 3 https://www.nejm.org/doi/full/10.1056...

• Evolut Low Risk https://www.nejm.org/doi/full/10.1056...

• Barili meta-analysis https://doi.org/10.1093/ejcts/ezab516


II. Renal Denervation


Alcohol-Mediated Renal Denervation Promising in Hypertension


https://www.medscape.com/viewarticle/...


• TARGET 1 https://www.ahajournals.org/doi/10.11...


III. Inclisiran


Earlier Inclisiran Gives Better Long-Term LDL Reductions


https://www.medscape.com/viewarticle/...


• VICTORIAN INITIATE Trial https://www.jacc.org/doi/10.1016/j.ja...


You may also like:


The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-h...


 Questions or feedback, please contact [email protected]